Background: It has been shown that decreased expression and activity of extracellular matrix protein mindin correlate with various types of cancers including breast, colon and lung cancers. The aim of the presented study was to investigate the serum mindin levels in prostate cancer.
Methods: Mindin concentrations in serum were measured in 56 patients with prostate cancer (mean age 68 years) and in control group of 29 healthy men (mean age 64 years) using commercially available enzymatic immunoassay (Cusabio, WuHan, China). The patients were divided with respect to the severity of the disease into two groups according to the EAU guidelines (stage 1, 2 - less severe tumours, stage 3, 4 - severe tumours).
Results: Serum mindin concentrations were significantly elevated in the group of healthy individuals unlike in the patients with prostate cancer (2.12 ng/mL vs 0.78 ng/mL, with P=0.0007, AUC=0.705). Patients with less severe tumours (stage 1, 2) and severe tumours (stage 3, 4) had significantly decreased levels of S-mindin as well (P=0.0037), although the difference in serum mindin concentrations between the patients with less severe and severe tumours was not significant.
Conclusions: Concentrations of mindin were decreased in patients with prostate cancer and reduced in patients with less severe prostate cancer as well. Mindin appears to be a promising diagnostic marker useful in the diagnosis of prostate cancer.
Uvod: Pokazalo se da je smanjena ekspresija i aktivnost ekstracelularnog proteinskog matriksa mindina korelira sa različitim tipovima raka, uključujući rak dojke, debelog creva i pluća. Cilj prikazane studije je bio da se ispita serumski nivo mindina kod karcinoma prostate.
Metode: Koncentracije mindina u serumu su merene kod 56 bolesnika sa karcinomom prostate (srednja starost 68 godina) i u kontrolnoj grupi od 29 zdravih muškaraca (srednja starost 64 godine) korišćenjem komercijalno dostupnog enzimskog testa (Cusabio, VuHan, Kina). Pacijenti su prema težini bolesti podeljeni u dve grupe prema EAU smernicama (faza 1, 2 - manje teški tumori, faza 3, 4 - teški tumori).
Rezultati: Koncentracije serumskog mindina bile su značajno povišene u grupi zdravih pojedinaca, za razliku od pacijenata sa rakom prostate (2,12 ng/mL u odnosu na 0,78 ng/mL, sa P=0,0007, AUC=0,705). Pacijenti sa manje ozbiljnim tumorima (faza 1, 2) i teškim tumorima (faza 3, 4) imali su i značajno snižene nivoe S-mindina (P=0,0037), iako razlika u koncentracijama mindina u serumu izme u pacijenata sa manje teškim i ozbiljnim tumori nije bila značajna.
Zaključak: Koncentracije mindina su smanjene kod pacijenata sa rakom prostate, a smanjene su i kod pacijenata sa manje teškim oblikom raka prostate. Izgleda da je mindin obećavajući dijagnostički marker i da je koristan u dijagnostici raka prostate.
Keywords: biomarker; mindin; prostate cancer.
2020 Lenka Hanousková, Jakub Řezáč, Štěpán Veselý, Richard Průša, Karel Kotaška, published by CEON/CEES.